Phase II Study of Docetaxel Plus CDDP for NSCLC Stage III

This study has been completed.
Information provided by (Responsible Party):
National Taiwan University Hospital Identifier:
First received: September 12, 2005
Last updated: December 19, 2012
Last verified: December 2012
To assess the overall response rate to docetaxel plus CDDP as neoadjuvant chemotherapy prior to surgery, followed by adjuvant docetaxel plus CDDP in chemonaive patients NSCLC Stage IIIa and IIIb.

Condition Intervention Phase
Drug: Docetaxel Plus CDDP
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Study Evaluating Docetaxel and CDDP as Neoadjuvant Chemotherapy Prior to Surgery, Followed by Adjuvant Docetaxel Plus CDDP in Chemonaive Patients With NSCLC Stage III

Resource links provided by NLM:

Further study details as provided by National Taiwan University Hospital:

Primary Outcome Measures:
  • overall response rate [ Time Frame: every cycle during 2nd-6th cycles ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • resectability [ Time Frame: resectability after treatment ] [ Designated as safety issue: No ]
  • progression free survival [ Time Frame: progression free survival after 1 year ] [ Designated as safety issue: No ]
  • overall survival [ Time Frame: overall survival at 1 year ] [ Designated as safety issue: No ]

Enrollment: 41
Study Start Date: February 2005
Study Completion Date: March 2010
Primary Completion Date: January 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: docetaxel and cisplatin
docetaxel 36mg/m2 and cisplatin 75mg/m2
Drug: Docetaxel Plus CDDP
docetaxel 36mg/m2 and cisplatin 75mg/m2


Ages Eligible for Study:   20 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically or cytologically confirmed NSCLC, respectable NSCLC stage IIIa T1-2 N2 or or unresectable stage IIIb 2.KPS>70% 3.Hb>10g/dl,ANC>2.0x109/L,Plt.>100x109/L4.T-bil.<1xULN,creatinine<1xULN,creatinine clearance >60 ml/min,GPT/GOT<2.5xULN,ALP<5xULN

Exclusion Criteria:

  • 1.Brain meta.2..Prior surgery,R/T, C/t or immunotherapy for NSCLC
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00172380

Department of Internal Medicine, National Taiwan University Hospital
Taipei, Taiwan, 100
Sponsors and Collaborators
National Taiwan University Hospital
Principal Investigator: Chong-Jen Yu, M.D,Ph.D. Department of Internal Medicine, National Taiwan University hospital
  More Information

Responsible Party: National Taiwan University Hospital Identifier: NCT00172380     History of Changes
Other Study ID Numbers: 930911 
Study First Received: September 12, 2005
Last Updated: December 19, 2012
Health Authority: Taiwan: Department of Health

Additional relevant MeSH terms:
Antimitotic Agents
Antineoplastic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators processed this record on April 27, 2016